[儿科大脑瘤] 这是什么?
1Institut für Neuropathologie, Hirntumor-Referenzzentrum der DGNN, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland. t.pietsch@uni-bonn.de.
Pathologie (Heidelberg, Germany)
|September 27, 2023
概括
儿童中枢神经系统 (CNS) 瘤需要精确的神经病理学分类才能有效治疗. 最近的进展,包括遗传和表观遗传分析,提高了诊断准确度,并指导了儿童大脑瘤的新疗法策略.
科学领域:
- 神经病理学神经病理学
- 儿科瘤学 儿科瘤学
- 分子生物学分子生物学
更多相关视频
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
3.5K
11:14Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors
Published on: September 24, 2014
15.8K
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
161
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
161
Pharmacokinetics in Pediatric Patients: Drug Distribution
182
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
182
Pharmacokinetics in Pediatric Patients: Drug Metabolism
121
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
121
